维生素D联合厄贝沙坦治疗IgA肾病的效果

目的探讨治疗IgA肾病采用活性维生素D联合厄贝沙坦的临床效果,以及对T细胞亚群的影响。方法选入本院于2017年3月-2018年4月期间所收治的IgA肾病患者92例,以随机数字表法的形式将分为观察组和参照组,各为46例。观察组行活性维生素D联合厄贝沙坦治疗,参照组行厄贝沙坦治疗,对比治疗前后两组患者相关指标参数、T淋巴细胞亚群变化。结果 (1)治疗4个月后两组患者的尿蛋白、血肌酐水平均比之治疗前低,且观察组的尿蛋白、血肌酐水平比参照组低,组间差异具有统计学意义(P <0.05),但两组患者的血钙水平差异不具备统计学意义(P> 0.05);(2)治疗4个月后,观察组的CD4^+、CD8^+、CD4^+/CD8^+均下降,且下降程度比参照组明显,组间对比P <0.05。结论活性维生素D联合厄贝沙坦对于IgA肾病患者而言,能够降低相关指标参数,且减低了CD4^+、CD4^+/CD8^+的变化,在临床治疗应用具有非常重要的意义。

Effect of Vitamin D Combined With Irbesartan on IgA Nephropathy

Objective To investigate the clinical effects of active vitamin D combined with irbesartan in the treatment of IgA nephropathy and its effect on T cell subsets. Methods Ninety-two patients with IgA nephropathy admitted to our hospital from March 2017 to April 2018 were randomly divided into observation group and reference group, each with 46 cases. The observation group was treated with active vitamin D combined with irbesartan. The reference group was treated with irbesartan. The relative parameters and T lymphocyte subsets of the two groups were compared before and after treatment. Results(1) After 4 months of treatment, the urine protein and serum creatinine levels in the two groups were lower than those before treatment, and the urine protein and serum creatinine levels in the observation group were lower than those in the reference group, and there were differences between the groups(P < 0.05). However, the blood calcium levels of the two groups were not statistically significant(P > 0.05).(2) After 4 months of treatment, the CD4^+, CD8^+, CD4^+/CD8^+ of the observation group decreased, and the degree of decline was more obvious than that of the reference group. P < 0.05. Conclusion Active vitamin D combined with irbesartan can reduce the related index parameters and reduce the changes of CD4^+ and CD4^+/CD8^+ in patients with IgA nephropathy, which is of great significance in clinical treatment.